Search Results

You are looking at 1 - 10 of 190 items for :

  • "Renal cell carcinoma" x
  • Refine by Access: All x
Clear All
Full access

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, and Sandy Srinivas

cases consist of renal cell carcinomas (RCCs), which are genetically and histologically distinct from cancers of the renal pelvis. An increased understanding of RCC biology coupled with new clinical trials data have resulted in the availability of

Full access

Selecting Targeted Therapies for Patients With Renal Cell Carcinoma

Elizabeth R. Plimack and Gary R. Hudes

metastatic clear cell RCC Describe second-line management of patients with metastatic clear cell RCC I n the past 5 years, 6 new agents were approved for the treatment of renal cell carcinoma (RCC). These can be broadly categorized into 2 groups: vascular

Full access

Optimal Management of Localized Renal Cell Carcinoma: Surgery, Ablation, or Active Surveillance

David Y. T. Chen and Robert G. Uzzo

Edited by Kerrin G. Robinson

: casting doubt on the efficacy of early intervention . Urology 2001 ; 57 : 1013 – 1015 . 3 Hollenbeck BK Taub DA Miller DC . National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology

Full access

Updates in the Systemic Therapy Options for Clear Cell and Non–Clear Cell Renal Cell Carcinoma

Presented by: Philippe E. Spiess, Peter A.S. Johnstone, and Eric Jonasch

Through the use of case studies, experts in renal cell carcinoma (RCC) explored the latest recommendations in the systemic treatment of patients with clear cell or non–clear cell disease at the NCCN 2023 Annual Conference. This discussion utilized

Full access

New Treatments for Renal Cell Carcinoma: Targeted Therapies

Philip J. Saylor and M. Dror Michaelson

Petrylak D Thompson S . Cytotoxic chemotherapy for advanced renal cell carcinoma . Urol Clin North Am 1993 ; 20 : 303 – 321 . 3 Atkins MB Regan M McDermott D . Update on the role of interleukin 2 and other cytokines in the treatment of

Full access

Role of Surgery for Locally Advanced and Metastatic Renal Cell Carcinoma

Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson

Historically, renal cell carcinoma (RCC) has been a formidable cancer with limited responses to both radiation and systemic management. Currently, surgery offers the only real chance of cure for patients with cancer localized to the kidney and

Full access

Improved Survival in Contemporary Community-Based Patients With Metastatic Clear-Cell Renal Cell Carcinoma Undergoing Active Treatment

Reha-Baris Incesu, Simone Morra, Lukas Scheipner, Andrea Baudo, Letizia Maria Ippolita Jannello, Mario de Angelis, Carolin Siech, Anis Assad, Zhe Tian, Fred Saad, Shahrokh F. Shariat, Felix K. H. Chun, Alberto Briganti, Ottavio de Cobelli, Luca Carmignani, Sascha Ahyai, Nicola Longo, Derya Tilki, Markus Graefen, and Pierre I. Karakiewicz

Background To date, no population-based study has reported a survival benefit in most contemporary community-based patients with clear-cell metastatic renal cell carcinoma (ccmRCC) receiving active treatment, relative to their historical

Full access

Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma

Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss

Background Brain metastases are a critical site of disease progression in patients with metastatic renal cell carcinoma (mRCC). Large institutional and population-based studies estimate the incidence of brain metastasis to be 5% to 20%, 1

Full access

Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options

Kelly N. Fitzgerald and Chung-Han Lee

Background Renal cell carcinoma (RCC) is the eighth most common malignancy in the United States; in 2020 alone, approximately 74,000 new cases of RCC were diagnosed and approximately 15,000 deaths were reported. 1 Historically, treatment

Full access

Ten Years of Progress in Renal Cell Carcinoma

Eric Jonasch and Robert J. Motzer

In the past 10 years, much has changed in the management of advanced renal cell carcinoma (RCC; Figure 1 ). The treatment of early-stage disease has become less morbid, with the widespread adoption of robotic surgical techniques and the increased